IL6R and head and neck squamous cell carcinoma: To determine the outcome of combination therapy with Cisplatin and IL-6R inhibitor Tocilizumab on the CSC fraction, we utilized HNSCC patient-derived xenograft (PDX) mouse models characterized by our laboratory [29].